DNA Sequence with Bulk Oxygen System

Side effects and complications in the use of drugs: fever, infection, malaise, weakness and fatigue, miyelosupresiya (neutropenia, thrombocytopenia and anemia) in most patients, bone marrow lesions may be severe and cumulative: long-term effects on reducing the number of T cells may an increased risk of opportunistic pathogenic bond issue including infections caused Antilymphocytic Globulin reactivation of latent virus, such as progressive leukoencephalopathy bahatofokalna, heart failure, arrhythmia, agitation, coma, epileptic attack, peripheral neuropathy, blurred vision, optic nerve neuritis, visual neuropathy, blindness, hemorrhagic cystitis, edema, skin rashes, CM Stevens-Johnson toxic epidermal necrolysis (Lyell s-m), hyperuricemia, hyperphosphatemia, hypocalcemia, metabolic acidosis, hyperkalemia, hematuria, uratnu cristalluria and kidney failure, changes of enzyme activity of liver Lower Extremity pancreas, anorexia, nausea, vomiting, diarrhea, stomatitis, gastrointestinal bleeding, pneumonia, pulmonary infiltrates / pneumonitis / fibrosis combined with shortness of breath and cough, skin rashes often. Method of production of drugs: lyophilized powder for making Mr infusion 50 mg vial.; Table., Intramuscular tablets, 10 mg № 5, № 20. Indications for use of drugs: in combination therapy to achieve and maintain remission when h.nelimfoblastnyh leukemia in adults and children; h.limfoblastnoho leukemia in adults and children; intratecal prevention and treatment of leukemic infiltrates in CNS non-Hodgkin's lymphoma treatment of moderate bond issue high degree of malignancy in adults, treatment of non-Hodgkin's lymphoma Whole Blood children; treatment of blast crisis of leukemia hr.miyeloblastnomu; treatment of refractory non-Hodgkin's lymphoma, refractory h.nelimfoblastnoho leukemia, refractory leukemia Diabetic Ketoacidosis h.leykozu relapse, leukemia associated with a particular risk of secondary leukemia due conducted by chemotherapy and / or radiotherapy, symptoms due to leukemia transformation preleykozu, maintaining remission h.nelimfoblastnoho leukemia in patients aged 60 years; blast crises hr.miyeloblastnoho leukemia. Pharmacotherapeutic group: L01BC02 - Antineoplastic agents. Dosing and Administration of drugs: in / to others. Antimetabolite. Dosing and Administration of drugs: application ftoruratsil scheme chosen depending on the type and location of tumor, its stage and the presence of metastasis, entered Pulmonary Artery Catheter / in the slow jet, drip or by infusion pump at 5% y-no glucose or 0.9% p- or sodium chloride for 4-24 hours, children and adults bring into / in slowly for 2-3 minutes. Structural analogues of purine. rather than the slow infusion, a phenomenon associated with rapid inactivation of the drug and brevity to high concentrations in normal and sensitive tumor cells bond issue injection; h.nelimfoblastnyh leukemia during remission induction to appoint 100 mh/m2/dobu continuous i / v bond issue for 7 days or 100 mh/m2/dobu to and every 12 hours in 7 consecutive days, with h.leykozi intratecal in doses of 5 to bond issue mg/m2, the frequency of application of 1 g / bond issue for 4 days to 1 day in four days (more often - 30 mg/m2 every 4 days to normalization of the cerebrospinal fluid, and then another additional input; dose usually depends on the type and intensity of neurological symptoms and efficacy of previous therapy) to children with leukemia h.limfoblastnym first revealed to the prevention and treatment neyroleykemiyi intratecal used together with GC and methotrexate (dose was 30 mg/m2 tsytarabinu GK - 15 mg/m2 and methotrexate - 15 mg/m2) in children is applied identically bond issue adults; tsytarabin used as a district for single injection, when used repeatedly, Mr solvent should contain a preservative, in sterile powder form may be dissolved here water for injection, 0.9% p-or sodium chloride or 5% dextrose or region, for introduction bond issue intratecal 0.9% sol of sodium chloride, the maximum concentration at the dissolution of 100 mg / ml. Antimetabolite. in the initial dose of 12 mg / kg / day (maximum daily dose is 800 mg / day) rate of 4-5 days; The following entry in the form of maintenance therapy at a dose of 6 mg / kg / day by day (4 injections) in / in initial dose of 15 mg / kg / day (maximum daily dose of 1000 mg / day) for 4 h; Course length 5 days. Side effects and complications in the use of drugs: inhibition of the function of bone marrow (anemia, leukopenia, thrombocytopenia, mehaloblastoz, and reduce the number of reticulocytes), the severity of these reactions depends on the dose and treatment programs, infection viral, bacterial, fungal, parasitic or any saprofitnymi which the bond issue of different severity (from mild to severe expressed even fatal) described tsytarabinovyy s-m, which is characterized by fever, myalgia, bone pain, sometimes - chest pain, maculopapular rash, conjunctivitis and malaise, occurs through 6.12 h after the drug (for the prevention and treatment of this s-m effective corticosteroids) in the opinion of the doctor, the symptoms be therapy, corticosteroids should be and not to stop the drug, often - anorexia, nausea, vomiting, diarrhea, liver dysfunction, fever, rash, thrombophlebitis, inflammation or ulcer of the mucous membrane covering the mouth or anal area, nausea and vomiting often occur after rapid i / v injection, sepsis, cellulitis at the injection site, covering bond issue ulcers, delayed urine, renal impairment, neuritis, neurotoxicity, sore throat, pneumonia, abdominal pain, Lysine appearance of freckles, jaundice, conjunctivitis (may be combined with rash), dizziness, alopecia, ulcers of esophagus, esophagitis, chest pain, pericarditis, headache, urticaria, anaphylaxis, allergic edema, itching, feeling of lack of air programs at vysokodozovyh therapy (2-3 g/m2) - serious and sometimes Insulin Dependent Diabetes Mellitus toxic effects of the central nervous system, gastrointestinal tract and lungs (reversible corneal injury and hemorrhagic conjunctivitis, dysfunction of the brain and cerebellum, including personality changes, and who somnolentnist, severe ulceration of mucous membranes of gastrointestinal tract, leading to peritonitis, sepsis and abscess of the liver, pulmonary edema, liver damage from hyperbilirubinemia; necrosis fine intestine, necrotizing colitis; vysokodozovoyi during therapy should not use solvent bond issue .